Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 5/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632621 | 0.88 | AR (0.40) | CNR2GPR55AR | |
| SCHEMBL806615 | 0.86 | CNR2 (0.45) | CNR2GPR55CYP2A6ALDH1A1L3MBTL1 | |
| SCHEMBL16632531 | 0.86 | SLC6A4 (0.42) | ARCYP2A6SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL16632622 | 0.86 | CNR2 (0.45) | CNR2GPR55ARCYP2A6ALDH1A1 | |
| SCHEMBL16632984 | 0.85 | CYP2A6 (0.45) | CNR2ARCYP2A6SMN1; SMN2ALDH1A1 | |
| SCHEMBL16632749 | 0.78 | MAPT (0.36) | CNR2ARALDH1A1L3MBTL1KDM4E | |
| SCHEMBL5584528 | 0.77 | CYP2A6 (0.50) | CNR2GPR55CYP2A6SMN1; SMN2ALDH1A1 | |
| SCHEMBL16632454 | 0.74 | AR (0.41) | CNR2ARCYP2A6L3MBTL1 | |
| SCHEMBL16632723 | 0.73 | SLC6A4 (0.49) | ARALDH1A1MAPK1HTTHSD17B10 | |
| SCHEMBL16632567 | 0.70 | CYP2A6 (0.38) | CNR2ARCYP2A6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | CNR2 4118/4885GPR55 2573/4885AR 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.